Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sernova Corp (OP: SEOVF )

0.2924 -0.0160 (-5.19%)
Streaming Delayed Price Updated: 11:25 AM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sernova Corp

Sernova Provides Positive Clinical and Platform Portfolio Update
With recent positive findings in post-surgical hypothyroidism large animal study, Sernova anticipates filing an Investigational New Drug (IND) application in 2024 
Via TheNewswire.com
Sernova Announces Peer Reviewed Publication Demonstrating Safety and Efficacy of a Novel Cell Pouch Cell Therapy Approach for Treatment of Severe Hemophilia A
LONDON, ONTARIO – TheNewswire - January 20, 2022 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine and cell therapy therapeutics company developing a... 
Via TheNewswire.com
Sernova to Present Corporate Update at Canaccord Genuity's 41st Annual Growth Conference
London, ON - TheNewswire - August 9, 2021 - Sernova Corp. (TSXV:SVA) (FSE/XETRA:PSH) (OTC:SEOVF), a leading clinical-stage company focused on regenerative medicine therapeutics, today announced that... 
Via TheNewswire.com
Exposures COVID-19
Sernova Announces 2021 Annual Meeting Results: Shareholders Approve Resolutions with Overwhelming Majority
LONDON, ONTARIO - TheNewswire - July 5, 2021 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, held its annual shareholder... 
Via TheNewswire.com
Exposures COVID-19
Industry Veteran Frank Shannon Joins Sernova as VP Clinical Development and Regulatory Affairs
25-Year Industry Veteran in Clinical/Regulatory Therapeutics Development 
Via TheNewswire.com
Exposures COVID-19
Sernova's Principal Investigator Presents Interim Data and Positive Patient Outcomes of Phase I/II T1D Study at the American Diabetes Association 81st Scientific Sessions
First Patient Successfully Completes Clinical Trial and Shares Study Experiences and Impact 
Via TheNewswire.com
Exposures COVID-19
Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference
Multiple patients with sustained clinical benefit, including positive fasting serum C-peptide (a biomarker of insulin produced by Sernova’s Cell Pouch islets) detected in their bloodstream 
Via TheNewswire.com
Exposures COVID-19
Sernova Announces American Transplant Congress 2021 Virtual Connect Abstract Presentation
London, Ontario - TheNewswire - June 1, 2021 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce that... 
Via TheNewswire.com
Exposures COVID-19
Sernova to Present at Global Partnership Family Office -- HealthCare & Biotechnology TSX Showcase
LONDON, ON – TheNewswire - May 17, 2021 -- Sernova Corp. (TSXV:SVA)(FSE/XETRA:PSH)(OTC:SEOVF), a leading clinical-stage company focused on regenerative medicine therapeutics, today announced that Dr.... 
Via TheNewswire.com
Sernova Announces the Nomination of Seasoned Pharma Executive Dr. Mohammad Azab to its Board of Directors
LONDON, ONTARIO – TheNewswire - May 4, 2021 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, today announced that seasoned... 
Via TheNewswire.com
Topics Retirement
Exposures Pension
Sernova KOL Event Highlights Novel Cell Therapy Approach for the Potential Treatment of Thyroid Disease
LONDON, ONTARIO – TheNewswire - April 28, 2021 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, announced today the... 
Via TheNewswire.com
Sernova to Host a Virtual Key Opinion Leader Event on Thyroid Disease and the Potential for its Cell Therapy as a Novel Treatment Approach
LONDON, ONTARIO – TheNewswire - April 21, 2021 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, today announced that it will... 
Via TheNewswire.com
Sernova Appoints Internationally Renowned Thyroid Disease Expert Dr. Sam Wiseman to its Scientific Advisory Board
Sernova Expands Scientific Advisory Board Expertise for its Innovative Cell Therapy Therapeutic Applications in Endocrine Disorders Including Thyroid Disease 
Via TheNewswire.com
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.